




UNIVERSITY *of* MARYLAND
SCHOOL OF MEDICINE

Survivorship: Lifestyle Modifications of Diet and Exercise

Alice S. Ryan, PhD
Professor

Division of Gerontology and Geriatric Medicine
University of Maryland School of Medicine
VA Senior Research Career Scientist

To Win We Have To Lose



Functional Limitations

- Compared to age and gender matched non-cancer controls:
 - Peak cardiorespiratory fitness is similar to the 20th percentile
 - ~20% lower strength
 - Recent and long-term (5+ years) more likely to report difficulties
 - ~50% report physical limitations (vs. 21%)
 - ~33% reported participation restrictions (vs. 13%)

Metabolic Abnormalities

- Weight gain is more common in patients:
 - Receiving chemo-, steroid, or hormonal therapy
 - Premenopausal women (for breast cancer)
- Sarcopenia is common in cancer survivors
- Compared to age-matched non-cancer controls, cancer survivors more likely to have T2DM and CVD risk factors

Is metabolic risk greater in cancer survivors than adults without a cancer history if matched for BMI?



**INSULIN RESISTANCE AND INFLAMMATION
IN BLACK WOMEN WITH AND
WITHOUT BREAST CANCER:
CAUSE FOR CONCERN**

Kathleen A. Griffith, PhD, MPH, CRNP¹; Seon-Yoon Chung, PLD, RN¹;
Shijun Zhu, PhD¹; Alice S. Ryan, PhD^{2,3}

Table 2. Comparisons on measures of insulin resistance, inflammation and lipids between women with and without breast cancer


Biomarker	Breast cancer		No Cancer					
	n=19		Similar age, n=25			Older, n=32		
	Mean	SD	Mean	SD	P	Mean	SD	P
Glucose, mmol/L	5.78	.84	5.27	.74	.042	5.16	.81	.012
Insulin, μ U/mL ^a	23.4	10.8	15.4	9.9	.001	14.3	7.6	<.001
HOMA-IR ^a	6.0	2.9	3.6	3.1	.001	3.2	1.4	<.001
C reactive protein, mg/dL	8.32	6.90	7.80	6.43	.826	5.09	6.09	.140
IL-1b, pg/mL	2.1	.7	1.1	.9	.001	1.1	.8	<.001
IL-6, pg/mL ^a	6.8	3.6	4.3	3.6	.007	6.7	8.1	.120
IL-8, pg/mL ^a	9.8	5.1	13.1	24.0	.245	10.4	24.2	.018
TNF- α , pg/mL	18.3	5.3	7.8	3.5	<.001	6.8	3.7	<.001
Triglycerides, mg/dL	99.9	58.6	94.7	31.3	.739	114.7	42.9	.324
Total cholesterol, mg/dL	184.4	23.5	189.5	31.0	.580	192.1	31.0	.372
HDL cholesterol, mg/dL	54.5	11.7	56.5	14.9	.669	48.9	9.5	.081
LDL cholesterol, mg/dL	109.5	26.7	114.4	27.8	.594	119.8	27.3	.217
Adiponectin, μ g/mL	12.9	8.4, n=17	19.3	9.9, n=11	.082	13.2	9.2, n=9	.938

Comparisons made to BC group using t-tests. Associated P values are reported.


a. Indicates variable transformed for analysis.

Metabolic Syndrome

- BCS are ~2.5x more likely to have Metabolic Syndrome (21% vs. 52%, $P < 0.05$)
- Blood pressure (64%) and waist circumference (61%) were the most prevalent components



Depression associated with worse metabolic profiles



*P<0.05, #P=0.07, ‡=0.09



Weight loss with mindful eating in African American women following treatment for breast cancer: a longitudinal study

SeonYoon Chung¹ · Shijun Zhu¹ · Erika Friedmann¹ · Catherine Kelleher¹ · Adriane Kozlovsky^{2,3} · Karen W. Macfarlane⁴ · Katherine H. R. Tkaczuk⁵ · Alice S. Ryan^{2,3} · Kathleen A. Griffith¹

Table 2 Changes in mindful eating assessment, weight, and BMI over time in African American women with treatment of breast cancer who participated in mindfulness eating intervention program for 6 months ($N=22$)

Characteristic	Baseline		Post-3 months		Post-6 months		β	Sig.
	Range	Mean (SD)	Range	Mean (SD)	Range	Mean (SD)		
MEQ	2.18–3.98	2.87 (0.400)	2.28–3.64	2.90 (0.44)	2.46–3.98	3.03 (0.405)	0.160	.001
Weight (kg)	59.87–142.30	92.44 (16.05)	59.87–136.26	91.53 (16.14)	63.59–142.30	92.00 (16.90)	−0.887	.015
BMI (kg/m^2)	27.08–47.21	35.13 (3.97)	25.10–47.75	34.30 (4.27)	26.66–49.87	34.47 (4.59)	−0.331	.014

Mindful Eating Questionnaire (MEQ) assessing mindful eating; score range is 1–4, higher is more mindful

BMI body mass index



Exercise Guidelines for Individuals with Cancer (ACSM 2018)

	Aerobic	Resistance	Flexibility
Frequency	3-5 d/wk	2-3 d/wk	≥2-3 d/wk with daily being most effective
Intensity	Moderate (64-75% HR _{max}) to vigorous (76-95% HR _{max})	Start with low resistance (e.g., <30% of 1-RM) and progress with smallest increments possible	Move through ROM as tolerated
Time	75 min/wk of vigorous intensity or 150 min/wk of moderate intensity activity or an equivalent combination of the two	At least 1 set of 8-12 repetitions	10-30 s hold for static stretching
Type	Prolonged, rhythmic activities using large muscle groups	Free weights, resistance machines, or weight-bearing functional tasks targeting all major muscle groups	Stretching or ROM exercises for all major muscle groups. Address specific areas of joint or muscle restriction that may have resulted from treatment with steroids, radiation, or surgery.


Exercise has modest positive effects on:

- 66 studies considered to be of high methodological quality —→
- Better outcomes with post-treatment vs. during treatment exercise (+
+++)
- Psychological Stress
 - Anxiety: ~15 studies: +
 - Pain: ~10 studies: +
 - QOL: ~25 studies; +
 - Depressive Symptoms: ~20 studies: ++
 - Fatigue: ~30 studies; +++
- Muscle Mass and Function
 - Lean Mass- ~10 studies; +
 - Aerobic fitness- ~25 studies; ++
 - Strength- ~15 studies; +++

Muscle Function


- 25-30% improvement in muscle strength

6 Minute Walk



↑4%, P=0.09



5 Chair Stands



↓16%, P<0.01

Mid-thigh Area



- Thigh muscle area increased and fat area decreased




*P<0.05

Metabolic Status


No changes in fasting or 2-hr glucose or lipid profiles



Inflammation



Piper Fatigue Index



Δ associated with initial: $r = -0.96$, $P < 0.01$

Physical Activity and Survival

✦ Survivors achieving weekly activity recommendations pre-diagnosis:

- Reduced Risk of Developing Cancer
 - ✦ 20-40%
- Reduced All-cause Mortality Risk
- 15-20%

Survivors and Physical Activity

- Benefits: Weight Gain and QOL
 - Reduce Risk of Cancer Recurrence
 - Improve Survival



Exercise Effect on Chemotherapy-Induced Neuropathic Pain, Peripheral Nerve Fibers

Determine the effects of aerobic exercise and resistive training versus attention control on CIPN and peripheral sensory fiber density in cancer survivors who have completed chemotherapy. 5R21HD091696-02 (Ryan/Griffith)

Progressive Activity-Based Rehabilitation in Veteran Cancer Survivors with Chronic Pain

VA SPiRE (Ryan/Griffith)

ACKNOWLEDGEMENTS

Monica Serra, PhD
Heidi Ortmeyer, PhD
Andrew Goldberg, MD

Kathleen Griffith, PhD, FNP-BC
SeonYoon Chung, PhD
Shijun Zhu, PhD
Katherine Tkaczuk, MD

NIH/National Institute of Aging
NIH/NIA: U of MD OAIC
NIH/NIDDK: Mid-Atlantic NORC
VA/ RR&D
VA GRECC